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Abstract: A series of analgesic activity of synthesised 1 -Phenyl-3-aryl-
5-(4-(butanoloxy) phenyl) 1H-pyrazoles were synthesized from chalcones 
and screened for their in vitro analgesic activity. Chalcones i.e.,1-aryl-3-
(4-hydroxyphenyl) prop-2-en-1-ones, 1 on reaction with phenyl hydrazine 
in presence of acetic acid and few drops of hydrochloric acid furnished the 
corresponding 1-phenyl-3-aryl-5-(4-hydroxyphenyl)-1H-pyrazoles 2 which 
on further reaction with 4-chloroalkanol yielded the title compounds 3. These 
compounds were characterized by CHN analyses, IR, mass and 1H NMR 
spectral data. All the novel synthesised 1-Phenyl-3-aryl-5-(4-(butanoloxy)
phenyl) 1H-pyrazoles were evaluated pharmacologically for their analgesic 
activity and the title synthesised compounds exhibited significant results as 
compared to standard drug. 
Keywords: Chalcones, 1H-pyrazoles, analgesic activity
1. INTRODUCTION
The most pervasive, frightening, and important symptom of injury, and much 
of disease, is pain. Pain should be considered a syndrome of highly unpleasant 
sensations rather than a symptom. Clinically pain is classified into two distinct 
types: acute and chronic. Acute pain is a set of unpleasant and emotional 
experiences often culminating in behavioural responses. Acute pain is, invariably, 
produced by disease, injury, noxious chemicals, or some physical stimulation 




have no biological function. It imposes physical, emotional, and social stresses 
of severe magnitudes (Abdel-Hafez et al., 2009). Heterocyclic compounds 
continue to create a center of attention due to their various biological activities. 
Amongst the five membered heterocles, pyrazoles have been found to exhibit 
wide application in the field of medicinal and pharmaceutical chemistry. In 
recent years, progressively more concentration has been given to the synthesis 
of pyrazole derivatives for the development of new antibacterial agents. 
Pyrazole derivatives have been reported to possess diverse biological activities 
such as antibacterial as suggested (Vogel, 2008); (Abdel-Aziz, et al., 2009), 
antifungal (Khalifa M.M., 2008), herbicidal (Chen and Li, 2000), insecticidal 
(Musad, 2011), anti-inflammatory, anticonvulsant (Goyal, 2012; Jain, 2013), 
anti-tumor, anti-oxidant (Jain et al., 2012) and so on. These reports prompted 
us to undertake the synthesis of some more 1H-pyrazoles bearing phenoxy 
alkanol moiety. The synthesized compounds were characterized on the basis of 
elemental analysis, IR, 1H NMR and mass spectral data. All the novel synthesised 
1-Phenyl-3-aryl-5-(4-(butanoloxy)phenyl) 1H-pyrazoles were evaluated 
pharmacologically for their analgesic activity and exhibited significant results 
as compared to standard drug.
2. EXPERIMENTAL
Chalcones 1a–g were synthesized by a base-catalyzed Claisen-Schmidt 
condensation reaction of appropriately substituted acetophenones and 
4-hydroxy benzaldehyde suggested by Youssef et al., 2010 and 1-phenyl-
3-aryl-5-(4-hydroxyphenyl)-1H-pyrazoles 2a–g were prepared from the 
chalcones 1a–g following the procedure described in the literature (Suwito 
et al., 2014) as shown in scheme 1. The purity of all the synthesized compounds 
was checked by thin layer chromatography on silica gel G as a stationary 
phase and different solvent systems as a mobile phase using iodine vapors 
as detecting agent. Melting points were determined by the Tempo melting 
point determination apparatus in open capillary tubes and are uncorrected. 
Infrared spectra were recorded on Shimadzu 8000 FTIR Spectrophotometer 
in KBr phase. Proton NMR spectra were done on Bruker Avance II 400 NMR 
Spectrometer using tetra-methyl silane as internal standard. Mass spectra of 
the compounds were carried out on Waters Micromass Q-Tof Micro Mass 
Spectrometer using electrospray ionization (ESI) technique. Elemental 
analyses were carried out on Perkin Elmer 2400 CHN Elemental Analyser.
General Procedure for the Synthesis of 1-phenyl-3-aryl-5-(4-(4-
butanoloxy phenyl)-1H-pyrazoles (3a–g). 1-phenyl-3-aryl-5-(4-hydroxy 
phenyl)-1H-pyrazoles (2a–g 0.01 M) and 4-chlorobutanol (0.01 M) were 
refluxed in acetone (50 mL) in the presence of tri-ethylamine (0.01 M) for 
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about four hours. Excess of solvent was removed under reduced pressure. The 
residue thus obtained was washed thoroughly with cold distilled water, dried, 
and then re-crystallized from ethanol. The physical and analytical data of the 






























1, 3-Diphenyl-5-(4-(4-butanoloxy) phenyl)-1H-pyrazole (3a): Yield: 
76%; m.p.: 81-83 oC; IR (KBr, cm–1): 3340 (O–H), 3070 (aromatic C–H 
str), 2916 (C–H), 1465, (CH2), 1255 (C–O–C), 1071 (C–O), 830, 732 & 690 
(aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 8.05-7.09 (m, 14H, ArH), 
7.02 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 3.69 
(s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.89-1.87 
(quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57-1.53 (quin, 2H, HO–CH2–
CH2–CH2–CH2–O–Ar); MS, m/z (%): 385 [M+H]
+ (100%). Anal.: Calcd. for 
C25H24N2O2: C, 78.10; H, 6.29; N, 7.29. Found: C, 78.16; H, 2.22; N, 7.21.
1-Phenyl-3-(4-methyl phenyl)-5-(4-(4-butanoloxy) phenyl)-1H-pyrazole 
(3b): Yield: 69%; m.p.: 87-89 oC; IR (KBr, cm–1): 3339 (O–H), 3065 (aromatic 
C–H str), 2919 (C–H), 1465, (CH2), 1255 (C–O–C), 1070 (C–O), 832, 730 
& 690 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 7.67-7.08 (m, 13H, 
ArH), 7.01 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 
3.69 (s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 2.34 
(s, 3H, CH3–Ar), 1.89-1.87 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57- 
1.53 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar); MS, m/z (%): 399 [M+H]
+ 
(100%). Anal.: Calcd. for C26H26N2O2: C, 78.36; H, 6.58; N, 7.03. Found: C, 
78.30; H, 6.51; N, 7.09.
1-Phenyl-3-(4-methoxy phenyl)-5-(4-(4-butanoloxy) phenyl)-1H-
pyrazole (3c): Yield: 71%; m.p.: 93-95 oC; IR (KBr, cm–1): 3343 (O–H), 3065 
(aromatic C–H str), 2916 (C–H), 1465, (CH2), 1255 (C–O–C), 1068 (C–O), 
832, 735 & 693 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 7.64-7.07 
(m, 13H, ArH), 7.02 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–
CH2–O–Ar), 3.83 (s, 3H, CH3O–Ar), 3.70 (s, 1H, O–H), 3.53-3.51 (t, 2H, 
HO–CH2–CH2–CH2–CH2–O–Ar), 1.89-1.87 (quin, 2H, HO–CH2–CH2–CH2–
CH2–O–Ar), 1.57-1.53 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar); MS, m/z 
(%): 415 [M+H]+ (100%). Anal.: Calcd. for C26H26N2O3: C, 75.34; H, 6.32; N, 
6.76. Found: C, 75.39; H, 6.38; N, 6.71.
1-Phenyl-3-(4-chloro phenyl)-5-(4-(4-butanoloxy) phenyl)-1H-pyrazole 
(3d): Yield: 77%; m.p.: 83-85 oC; IR (KBr, cm–1): 3336 (O–H), 3061 (aromatic 
C–H str), 2916 (C–H), 1465, (CH2), 1255 (C–O–C), 1066 (C–O), 832, 730 
& 690 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 8.01-7.07 (m, 13H, 
ArH), 7.01 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–CH2–O–
Ar), 3.70 (s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 
1.89-1.87 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57-1.53 (quin, 2H, 
HO–CH2–CH2–CH2–CH2–O–Ar); MS, m/z (%): 419 [M+H]
+ (100%), 421 
[M+2+H]+ (35%).Anal.: Calcd. for C25H23ClN2O2: C, 71.68; H, 5.53; 8.46; N, 
6.69. Found: C, 71.61; H, 5.58; N, 6.62.
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pyrazole(3e): Yield: 76%; m.p.: 95-97 oC; IR (KBr, cm–1): 3337 (O–H), 3066 
(aromatic C–H str), 2919 (C–H), 1465, (CH2), 1256 (C–O–C), 1072 (C–O), 
832, 732 & 695 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 7.79-7.08 
(m, 13H, ArH), 7.01 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–
CH2–O–Ar), 3.68 (s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–
CH2–O–Ar), 1.89-1.87 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57-
1.53 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar); MS, m/z (%): 463 [M+H]
+ 
(100%), 465 [M+2+H]+ (98%). Anal.: Calcd. for C25H23BrN2O2: C, 64.80; H, 
5.00; N, 6.05. Found: C, 64.87; H, 5.06; N, 6.10.
1-Phenyl-3-(4-fluoro phenyl)-5-(4-(4-butanoloxy) phenyl)-1H-pyrazole 
(3f): Yield: 74%; m.p.: 91-92 oC; IR (KBr, cm–1): 3340 (O–H), 3073 (aromatic 
C–H str), 2917 (C–H), 1465, (CH2), 1255 (C–O–C), 1070 (C–O), 830, 730 
& 692 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 8.15-7.08 (m, 13H, 
ArH), 7.02 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–CH2–O–
Ar), 3.69 (s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 
1.89-1.87 (quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57-1.53 (quin, 2H, 
HO–CH2–CH2–CH2–CH2–O–Ar); MS, m/z (%): 403 [M+H]
+ (100%). Anal.: 
Calcd. for C25H23FN2O2: C, 74.61; H, 5.76; N, 6.96. Found: C, 74.67; H, 5.71; 
N, 6.90.
1-Phenyl-3-(4-nitrophenyl)-5-(4-(4-butanoloxy) phenyl)-1H-pyrazole 
(3g): Yield: 72%; m.p.: 87-88 oC; IR (KBr, cm–1): 3342 (O–H), 3065 (aromatic 
C–H str), 2918 (C–H), 1465, (CH2), 1255 (C–O–C), 1070 (C–O), 832, 735 & 
690 (aromatic C–H def); 1HNMR (CDCl3): δ (ppm) 8.35-7.08 (m, 13H, ArH), 
7.01 (s, 1H, =CH–), 4.08-4.06 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 3.70 
(s, 1H, O–H), 3.53-3.51 (t, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.89-1.87 
(quin, 2H, HO–CH2–CH2–CH2–CH2–O–Ar), 1.57-1.53 (quin, 2H, HO–CH2–
CH2–CH2–CH2–O–Ar); MS, m/z (%): 430 [M+H]
+ (100%). Anal.: Calcd. for 
C25H23N3O4: C, 69.92; H, 5.40; N, 9.78. Found: C, 69.98; H, 5.47; N, 9.72.
Analgesic Activity. The experimental protocol was approved by the 
institutional animal ethical committee and care of the animals was done as 
per the guidelines of Committee (Chitkara College of Pharmacy) for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA), 
Ministry of Environment and Forests, Government of India (Reg. No.1181/
ab/08/CPCSEA). Wistar rats of either sex weighing 170-230g obtained from 
the Department of Livestock Production and Management, Guru Angad Dev 
Veterinary and Animal Sciences University, Ludhiana, India maintained on 
standard laboratory diet (Ashirwad Feeds Ltd., Chandigarh, India).
The analgesic activity of the synthesized title compounds was evaluated 




Phenylbutazone was used as a standard drug. A dose of 100 mg/kg   body 
weight was given orally as suspension of tween 80 (1% w/v, in distilled water). 
The response time was observed after 15 min, 30 min, 45 min and 60 min. post 
administration of drug. Percentage of Analgesic Activity (PAA) was calculated 
by the following formula.
PAA = (T2 – T1/ T1) × 100
Where T1 and T2 are the reaction time in seconds before and after 
treatment of drug(s) respectively. Data were statistically analysed and all the 
title compounds showed significant analgesic activity (P < 0.001).
3. RESULTS AND DISCUSSION
Chemistry. The syntheses of 1-phenyl-3-aryl-5-(4-(4-butanoloxy) phenyl) 
1H-pyrazoles were achieved following the steps outlined in the scheme 1. 
Chalcones i.e., 1-aryl-3-(4-hydroxyphenyl) prop-2-en-1-ones, 1 were prepared 
by the reaction of 4-hydroxy benzaldehyde with substituted acetophenones 
following the Claisen-Schmidt reaction. The chalcones 1 then on refluxing with 
phenyl hydrazine in the presence of acetic acid and few drops of hydrochloric 
acid furnished 1-phenyl-3-aryl-5-(4-hydroxyphenyl)-1H-pyrazoles 2. 
4-Chlorobutanol reacted with 2 in the presence of triethyl amine to give the 
3. All the compounds were obtained in good yield. These compounds were 
characterized on the basis of elemental and spectral analyses. IR spectra of each 
compound showed a band for O–H stretching vibrations for intermolecular 
hydrogen bonding near 3340 cm–1 while the C–O stretching vibrations for 
primary alcohols were observed in the range of 1075-1066 cm–1. C–O–C 
stretching vibrations for aryl alkyl ether were appeared at 1255 cm–1. The C–H 
stretching vibrations for methylene groups were appeared in the range of 2916-
2919 cm–1 whereas bending vibrations for methylene scissoring were observed 
constantly at 1465 cm–1. Aromatic C–H stretching vibrations were observed in 
the range of 3073-3061 cm–1 whereas aromatic C–H bending vibrations were 
appeared below 900 cm–1. In case of 1H NMR, the chemical shift value for the 
O–H group was observed in the range of 3.70-3.68 δ (ppm) and appeared as 
singlet (s). Aromatic protons appeared as multiplet (m) in the range of 8.35-
7.07 δ (ppm). The methine proton of the pyrazole nucleus absorbed at 7.02-
7.01 δ (ppm) and appeared as singlet (s). The methylene protons adjacent to 
the O–H group [HO–CH2–CH2–CH2–CH2–O–Ar] were appeared as triplet (t) 
in the range of 3.53-3.51 δ (ppm) whereas the methylene protons adjacent to 
the O–Ar group [HO–CH2–CH2–CH2–CH2–O–Ar] were observed at 4.08-4.06 
δ (ppm) and appeared as triplet (t). The central methylene protons which are 
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Change in reaction time
(seconds) (Mean ± SEM)
% Analgesic Activity
(Mean ± SD)
After 02 h After 04 h After 02 h After o4 h
3a 3.5 ± 0.14 2.4± 0.09 3.2± 0.3 142.72± 0.08 116..78± 0.07
3b 3.8± 0.42 2.56± 0.09 1.79± 0.09 138.90± 0.09 135.84±0.087
3c 3.6 ± 0.15 2.25± 0.09 1.79± 0.75 146.30±0.067 146.17± 0.06
3d 3 ± 0.07 2.1 ± 0.034 1.27± 0.87 155.69±0.42 106.8±0.056
3e 3.36 ± 0.05 4.10± 0.08 1.70± 0.056 134±0.045 130.7± 0.07
3f 3 ± 0.07 3.39±0.076 1.70± 0.45 119.09±0.054 155.8±0.056
3g 2.88 ± 0.08 3.40±0.043 1.58± 0.10 118.85± 0.12 160.12± 0.08
Control 4.74± 0.09 4.91± 0.03 4.91± 0.04 16± 0.06 15± 0.078
Phenyl-
butazone
3.2± 0.04 3.8± 0.06 4.8± 0.05 119.83± 0.08 110± 0.098
nearer to the O–H group appeared as quintet (quin) at 1.57-1.53 δ (ppm) and 
those are nearer to O–Ar group appeared at 1.89-1.87 δ (ppm) respectively. 
Aromatic methyl and methoxy protons were observed at 2.34 δ (ppm) and 3.83 
δ (ppm) respectively as singlet (s). All the title compounds showed [M+H]+ 
of 100% intensity as the molecular ion peak. Compound containing chlorine 
showed isotopic peak at [M+2+H]+ of about 35% intensity to that of parent 
ion peak whereas bromo derivative showed isotopic peak at [M+2+H]+ of 
about equal intensity. The results of elemental analyses were found in good 
agreement with the calculated values.
Analgesic activity. All the novel synthesised series, 1-Phenyl-3-aryl-5-(4-
(butanoloxy)phenyl) 1H-pyrazoles (3a-3g), were evaluated pharmacologically 
for their analgesic activity and some of them exhibited significant results as 
compared to standard drug.
It was also observed that the activity was also affected by the substituents 
present on the phenyl ring attached to position -3 and position-5 of the pyrazole 
nucleus. The order of activity was found to be in the following manner:




The title compounds (3d) containing chlorophenyl group attached to 
position-5 of the pyrazole nucleus were found to be most active and the 
compounds having nitro (3g) phenyl group were found to be least active.
4. CONCLUSION
Present study describes the synthesis of a series of 1-phenyl-3-aryl-5-(4-(4-
butanoloxy) phenyl)-1H-pyrazoles starting from the chalcones. The compounds 
were characterized by modern analytical techniques such as CHN analyses, 
IR, Mass and proton NMR spectra. The analgesic activity of the synthesized 
title compounds was evaluated by using tail-flick method in albino wistar mice 
(170-230g) of either sex.
Data were statistically analysed and all the title compounds showed 
significant analgesic activity (P < 0.001).
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